Arcutis Biotherapeutics, Inc. - Common stock (ARQT)

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Arcutis Q3 2025 Earnings Call Transcript

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Arcutis Biotherapeutics had an excellent update for investors and its future looks bright.

Arcutis Biotherapeutics smashed quarterly calls Tuesday and reported its first-ever positive net income.

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.

Arcutis (ARQT) Q3 2025 earnings crush estimates with a surprise profit. Revenue of $99.2M beats forecasts, driving the stock up 16% on strong ZORYVE demand.

Discover ARQT stock, a top growth pick blending Minervini's strong trend template with explosive earnings and sales momentum for potential outperformance.

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

Discover how Arcutis Biotherapeutics (ARQT) fits Mark Minervini’s Trend Template with strong technicals, high growth momentum, and fast-improving earnings—ideal for growth investors.

Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings.

Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema.

A fundamental and technical analysis of (NASDAQ:ARQT): Is ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) suited for high growth investing?